# Amniocentesis vs. CVS: Indications, Risks and Results

> A side-by-side guide to the two diagnostic prenatal tests that provide definitive chromosomal answers — who needs them, how they differ, and what the real miscarriage numbers say.

*Published 2026-06-25 · By Priya Nair, MD*

The short answer
Amniocentesis and CVS are the only prenatal tests that deliver a definitive chromosomal diagnosis. CVS is done at 10–13 weeks; amniocentesis at 15–20 weeks. In experienced hands, ACOG places the procedure-related miscarriage risk at roughly 1 in 769 for amniocentesis and 1 in 455 for CVS — meaningful but lower than many families expect.

When a screening result — whether from NIPT, a serum screen, or an anomaly spotted on ultrasound — raises a concern about the fetus's chromosomes, the next step in clinical care is often a conversation about *diagnostic* testing. Screening tests estimate probability; diagnostic tests answer the question definitively. Chorionic villus sampling (CVS) and amniocentesis are the two available diagnostic options, and understanding how they differ can help you and your care team make the decision that fits your timeline, your risk tolerance, and your family's values.

*This article provides general educational information, not individualized medical advice. Always discuss your specific circumstances, gestational age, and lab options with your OB-GYN, maternal-fetal medicine specialist, or genetic counselor.*

## How do amniocentesis and CVS actually work?

Both procedures retrieve fetal genetic material under continuous ultrasound guidance — the real-time imaging is what makes them safe enough to be offered routinely in experienced centers. What they retrieve, and when, is where they diverge.

**Chorionic villus sampling (CVS)** removes a small sample of chorionic villi — the finger-like projections of placental tissue that are genetically identical to the fetus. The sample can be retrieved by one of two routes: transabdominal (a needle through the mother's abdomen) or transcervical (a thin catheter passed through the cervix). The operator chooses the route based on placental location and anatomy. CVS is performed between **10 and 13 weeks of gestation**, making it the earliest available option for a definitive chromosomal answer.

**Amniocentesis** withdraws a small volume — typically 20 to 30 mL — of amniotic fluid from the sac surrounding the fetus. That fluid contains cells shed by the fetus (amniocytes), which carry the fetus's full chromosomal complement. The procedure is performed transabdominally under ultrasound guidance, most commonly between **15 and 20 weeks of gestation**. In some clinical situations (such as testing for fetal infection or assessing lung maturity in late pregnancy), amniocentesis may be performed later in the third trimester.

  Amniocentesis vs. CVS at a Glance

      Feature
      CVS
      Amniocentesis

      Gestational timing
      10–13 weeks
      15–20 weeks (sometimes later)

      What is sampled
      Placental villi (tissue)
      Amniotic fluid (fetal cells)

      Route
      Transabdominal or transcervical
      Transabdominal

      ACOG miscarriage risk
      ~1 in 455 (0.22%)
      ~1 in 769 (0.13%)

      Confined placental mosaicism
      ~2% of results (may need follow-up amnio)
      Not applicable (samples fetal cells directly)

      Result turnaround (CMA)
      5–10 business days
      5–10 business days

      Rapid FISH available
      Yes (24–48 hours)
      Yes (24–48 hours)

      Primary analytic method (ACOG)
      Chromosomal microarray (CMA)
      Chromosomal microarray (CMA)

## What are the real risks — and who should consider proceeding?

Miscarriage risk is the question families ask first, and the honest answer is that the risk is real but lower than popular perception often suggests.

[ACOG Practice Bulletin No. 162](https://www.contemporaryobgyn.net/view/acog-clinical-guidelines-glance-prenatal-diagnostic-testing-genetic-disorder) quantifies the procedure-related pregnancy loss rate — meaning risk above background — at approximately **1 in 769 for amniocentesis** (roughly 0.13%) and **1 in 455 for CVS** (roughly 0.22%) in experienced hands. These are not the same as overall miscarriage rates at these gestational ages; they represent the additional risk attributable to the procedure itself. Some large contemporary series at high-volume centers have reported amniocentesis loss rates approaching 0.1%, suggesting the published ACOG estimate may even be slightly conservative when a skilled operator is involved.

CVS carries a modestly higher procedural risk for two compounding reasons: it is performed earlier in pregnancy, when background spontaneous loss rates are naturally higher, and approximately 2% of CVS results show confined placental mosaicism (CPM) — a finding in which the chromosomal abnormality exists only in the placenta, not in the fetus. When CPM is found, a follow-up amniocentesis is typically recommended to clarify the fetal karyotype, which means some patients end up having both procedures.

As for who should consider proceeding: ACOG Practice Bulletin No. 162 broadened the traditional high-risk indications. Today, **any pregnant individual who wants a definitive chromosomal result** should be offered the option, regardless of age or whether they fall into a classically high-risk category. Specific indications include an abnormal NIPT or serum screening result, a fetal structural anomaly found on ultrasound, advanced maternal age (35 or older at delivery), a prior affected pregnancy, parental carriage of a chromosomal rearrangement, or a family history of a monogenic disorder such as cystic fibrosis, sickle cell disease, or Tay-Sachs disease.

Important context on risk
The ACOG miscarriage figures — 1 in 769 for amnio, 1 in 455 for CVS — represent additional risk above background. In high-volume centers, amnio rates may be closer to 1 in 1,000. Ask your provider about their center's specific procedural outcomes before deciding.

## How are the results analyzed — and what does chromosomal microarray actually detect?

Retrieving the sample is only the first step; the analytic method applied to it determines how much information you receive.

**Chromosomal microarray analysis (CMA)** is now the ACOG-recommended primary analytic method for both CVS and amniocentesis specimens, per Practice Bulletin No. 162. CMA scans the entire genome simultaneously for submicroscopic deletions and duplications — called copy-number variants (CNVs) — that a standard karyotype cannot detect. A conventional karyotype shows only large chromosomal changes visible under a light microscope; CMA resolves abnormalities at the kilobase scale, identifying conditions like DiGeorge syndrome (22q11.2 deletion) that a karyotype would miss entirely. CMA also does not require cells to be cultured, which shortens the wait compared to a traditional karyotype.

In practice, many centers offer a tiered approach: **rapid FISH** (fluorescence in situ hybridization) tests for the most common aneuploidies — trisomies 21, 18, and 13, and sex-chromosome abnormalities — and typically returns results in 24 to 48 hours. CMA results follow in 5 to 10 business days with the comprehensive picture. When a structural fetal anomaly is detected on ultrasound and CMA comes back normal, exome sequencing of the amniotic fluid or CVS sample is an emerging option that can identify single-gene variants; ACOG does not yet endorse routine exome or genome sequencing outside of a specialized clinical or research context.

Results are used to confirm or rule out the suspected chromosomal finding, to guide obstetric management (including delivery timing, delivery hospital level, and neonatal subspecialty planning), and to give families the definitive information they need for counseling and decision-making. A genetic counselor — who can be provided through many diagnostic laboratories at no additional cost — plays a critical role in explaining what a result does and does not mean for the pregnancy and for future family planning.

## CVS or amniocentesis: how to frame the decision with your provider

The most important variable in the CVS-vs.-amniocentesis decision is often **gestational age**. If you are still in the first trimester and want answers as early as possible — perhaps because early results allow more time for counseling, specialist consultation, or decision-making — CVS is the only option. If you are past 14 weeks, amniocentesis becomes available and is the more common choice at most centers.

A few other considerations are worth raising with your provider:

  - **Operator experience matters substantially.** Procedure-related risk is strongly correlated with the number of procedures a clinician has performed. Ask how many CVS or amniocentesis procedures your provider or center performs annually, and what their center-specific complication rates are.

  - **Placental location affects CVS route.** A posterior or fundal placenta may make transcervical CVS difficult; the transabdominal route or amniocentesis may be the preferred path.

  - **The 2% CPM rate with CVS.** If a CVS result comes back mosaic, a follow-up amniocentesis is often recommended. Factor this into your timeline if gestational age is a concern.

  - **Your reason for testing.** If the indication is confirming an abnormal NIPT result for trisomy 21, either procedure will provide that answer. If the indication is a structural anomaly on ultrasound, your MFM specialist may have a preference based on what additional analytic detail is needed.

Finally, it is entirely reasonable to decline diagnostic testing, choose to proceed based on screening results alone, or take time to discuss with a genetic counselor before deciding. ACOG frames the offer of diagnostic testing as expanding options, not mandating a particular path. Both procedures have a strong safety record in experienced hands, and the information they provide — definitive, actionable, and not obtainable any other way — remains the reason they continue to be offered as standard care in 2026.

## Sources

1. [ACOG Clinical Guidelines at a Glance: Prenatal diagnostic testing for genetic disorders](https://www.contemporaryobgyn.net/view/acog-clinical-guidelines-glance-prenatal-diagnostic-testing-genetic-disorder)
2. [Amniocentesis](https://www.acog.org/womens-health/faqs/amniocentesis)
3. [Fetal loss after amnio or CVS — what is the risk?](https://www.obgproject.com/2016/07/21/study-147987-women-asks-question-amniocentesis-chorionic-villus-sampling-cvs-increases-womans-risk-miscarriage-stillbirth-positive-screening-test/)
4. [Comparative analysis of obstetric, perinatal, and neurodevelopmental outcomes following chorionic villus sampling and amniocentesis](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239381/)
5. [Chorionic Villus Sampling (CVS): What It Is, Benefits & Risks](https://my.clevelandclinic.org/health/diagnostics/4028-chorionic-villus-sampling-for-prenatal-diagnosis)
6. [Chorionic Villus Sampling — Indications, Procedure, Risks](https://teachmeobgyn.com/operations-procedures/obstetric/chorionic-villus-sampling/)
7. [An overview of current prenatal genetic screening and diagnosis guidelines](https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/pmf2.70016)
8. [Is Amniocentesis after CVS Risky?](https://pmc.ncbi.nlm.nih.gov/articles/PMC11132116/)

---
Source: https://natalnew.com/prenatal-care/amniocentesis-vs-cvs
Index: https://natalnew.com/llms.txt · Full text: https://natalnew.com/llms-full.txt